|1.||Zamboni, William C: 2 articles (10/2011 - 04/2004)|
|2.||Tonda, Margaret: 2 articles (10/2011 - 08/2002)|
|3.||Martin, F: 2 articles (02/2010 - 10/2006)|
|4.||Davis, Whitney L: 1 article (10/2011)|
|5.||Dedrick, Robert: 1 article (10/2011)|
|6.||Yu, Ning: 1 article (10/2011)|
|7.||Beijnen, Jos H: 1 article (10/2011)|
|8.||Caron, Whitney P: 1 article (10/2011)|
|9.||Ramanathan, Ramesh K: 1 article (10/2011)|
|10.||Schellens, Jan H: 1 article (10/2011)|
10/01/2011 - "PK studies ofS-CKD602, Doxil®, and SPI-077 were performed at the maximum tolerated dose (MTD) in male and female mice, rats, dogs and patients with refractory solid tumors. "
04/20/2001 - "A phase I study was conducted to determine the toxicity and pharmacokinetics of SPI-77 administered to children with advanced cancer not amenable to other treatment. "
11/01/1999 - "The pharmacokinetic studies revealed a prolonged circulation time and enhanced tumor uptake for SPI-077. "
03/01/2005 - "SPI-077 alone resulted in a tumor growth delay, but combination with TNF had no additive effect. "
04/01/2004 - "There was no detectable unbound Pt in tumor ECF after SPI-077 or SPI-077 B-103 treatment. "
|2.||Sarcoma (Soft Tissue Sarcoma)
03/01/2005 - "Addition of TNF to SPI-077 treatment showed an improved tumor growth delay of the soft-tissue sarcoma. "
03/01/2005 - "In this study, we examined the effect of repeated systemic applications of low-dose TNF on the antitumor activity of SPI-077 in rats with soft-tissue sarcoma or osteosarcoma. "
|4.||Lung Neoplasms (Lung Cancer)
|7.||Platinum Compounds (Compounds, Platinum)
|8.||Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
|9.||BBR 3464 (BBR3464)